Integra LifeSciences Holdings Co. (NASDAQ:IART) Short Interest Update

Integra LifeSciences Holdings Co. (NASDAQ:IART) was the target of a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 4,100,000 shares, a decrease of 20.8% from the October 31st total of 5,180,000 shares. Based on an average daily volume of 974,300 shares, the short-interest ratio is presently 4.2 days. Approximately 6.2% of the company’s shares are short sold.

Institutional Trading of Integra LifeSciences

Several institutional investors have recently added to or reduced their stakes in IART. Blue Trust Inc. boosted its stake in shares of Integra LifeSciences by 100.5% in the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock worth $26,000 after buying an additional 444 shares during the last quarter. CWM LLC boosted its stake in shares of Integra LifeSciences by 50.8% in the 2nd quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock worth $37,000 after buying an additional 425 shares during the last quarter. KBC Group NV boosted its stake in shares of Integra LifeSciences by 65.2% in the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock worth $52,000 after buying an additional 1,120 shares during the last quarter. Canada Pension Plan Investment Board purchased a new position in shares of Integra LifeSciences in the 2nd quarter worth $114,000. Finally, Northwest Investment Counselors LLC purchased a new position in shares of Integra LifeSciences in the 3rd quarter worth $73,000. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have commented on IART. Truist Financial lowered their price target on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a research report on Monday, October 14th. Citigroup increased their target price on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research report on Tuesday, November 5th. Bank of America decreased their target price on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research report on Monday, October 7th. Morgan Stanley began coverage on Integra LifeSciences in a research report on Monday. They issued an “underweight” rating and a $20.00 target price for the company. Finally, BTIG Research raised Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, Integra LifeSciences has an average rating of “Hold” and an average price target of $23.00.

Integra LifeSciences Stock Performance

IART remained flat at $24.58 during trading on Monday. The company’s stock had a trading volume of 572,644 shares, compared to its average volume of 1,086,802. The business’s 50-day moving average is $20.77 and its 200 day moving average is $23.96. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. Integra LifeSciences has a 1-year low of $16.81 and a 1-year high of $45.42. The firm has a market cap of $1.90 billion, a PE ratio of -273.11, a price-to-earnings-growth ratio of 0.84 and a beta of 1.08.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.39 by $0.02. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The business had revenue of $380.80 million for the quarter, compared to the consensus estimate of $375.81 million. During the same period last year, the business posted $0.76 EPS. The company’s revenue was down .4% compared to the same quarter last year. On average, equities analysts expect that Integra LifeSciences will post 2.45 EPS for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.